Drug intelligence / Profile preview

GW9135

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GW9135 is a **PPARpan agonist**, a small molecule compound that activates all three subtypes of peroxisome proliferator-activated receptors (PPARα, PPARγ, and to a lesser extent, PPARδ). It shows highest potency at PPARα and significant activity at PPARγ, with weaker potency at PPARδ. GW9135 has demonstrated the ability to induce transient weight loss and reduce fat mass in animal models, but with compensatory weight regain during continued dosing. Like other strong PPAR agonists, it also increases liver weight. It is used primarily as a research compound to study metabolic and obesity-related processes.[1][3]

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)PPARD (Peroxisome proliferator–activated receptor delta)

Beyond the preview

Go deeper on GW9135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW9135.

Explore the full profile